Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences
Vivoryon Therapeutics N.V. announces participation in two key investor conferences:
- Van Lanschot Kempen Life Sciences Conference on April 25-26, 2023, featuring one-on-one meetings in Amsterdam.
- Bio€quity Europe on May 14-16, 2023, with a presentation scheduled for May 16, 2023, at 10:44 am IST in Dublin.
As a clinical-stage biotechnology company, Vivoryon focuses on developing small molecule medicines aimed at modulating pathologically altered proteins, including its lead program, varoglutamstat, which targets Alzheimer’s disease in Phase 2 clinical development. The company is committed to advancing treatments for severe diseases, utilizing extensive expertise in protein modifications.
- None.
- None.
Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences
Halle (Saale) / Munich, Germany, April 24, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that the Company’s management will participate in the following investor conferences:
Van Lanschot Kempen Life Sciences Conference Amsterdam (April 25-26, 2023)
Date: April 25, 2023
Only one-on-one meetings
Venue: Van Lanschot Kempen Office; Amsterdam, The Netherlands
Bio€quity Europe (May 14-16, 2023)
Date: May 16, 2023
Presentation Time: 10:44 am IST
Venue: Convention Centre Dublin; Dublin, Ireland
###
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Beyond our lead program, varoglutamstat, which is in Phase 2 clinical development to treat Alzheimer’s disease, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis. www.vivoryon.com
Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of the Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.
For more information, please contact:
Investor Contact
Stern IR
Julie Seidel
Tel: +1 212-698-8684
Email: SternIR-Vivoryon@sternir.com
Media Contact
Trophic Communications
Valeria Fisher
Tel: +49 175 8041816
Email: vivoryon@trophic.eu
FAQ
What is Vivoryon Therapeutics participating in on April 25-26, 2023?
When is Vivoryon's presentation at Bio€quity Europe?
What are the main focus areas of Vivoryon Therapeutics?
What is the role of varoglutamstat in Vivoryon's pipeline?
Where can I find more information about Vivoryon Therapeutics?
